

For Public Release
NZX Limited
Wellington

27 October 2023

Successful Verification for Oral Solution Products

Cannasouth Limited (**NZX:CBD**) is pleased to announce the successful assessment of its first two CBD Oral Solutions products by the Medicinal Cannabis Agency (Agency).

CBD oral solutions constitute a major segment in the New Zealand and Australian medicinal cannabis markets. The verification by the Agency will enable the two CBD Oral Solution products to be launched immediately to the New Zealand market and positions Cannasouth to capture a significant share of the local market.

Cannasouth CEO Mark Lucas says "This product launch is a pivotal moment for both Cannasouth and the industry at large. It addresses a critical issue: affordability for New Zealand patients.

"Our merger with Equis Group has enabled us to leverage innovative technologies in medicinal cannabis processing, significantly reducing production costs and, by extension, prices to patients.

"The key to unlocking rapid growth in the medicinal cannabis sector lies in balancing quality, cost, and accessibility to meet or outperform the black market. This product verification is a significant stride toward that end."

Prior to the Medicinal Cannabis Scheme's new regulatory standards, Equis Pharmaceutical Ltd was one of the largest CBD product suppliers in New Zealand.

Chief Innovation Officer Greg Misson notes, "Our goal is to disrupt the industry's economics through technology and innovation. This will not only secure our market position but also deliver value to our shareholders and improve patient access to quality medicinal cannabis."

Cannasouth has a pipeline of new products in development and/or the assessment process, with verification of the first New Zealand dried flower product expected imminently.

A list of all medicinal cannabis products that meet the New Zealand minimum quality standard can be found here: <https://www.health.govt.nz/our-work/regulation-health-and-disability-system/medicinal-cannabis-agency/medicinal-cannabis-agency-information-health-professionals/medicinal-cannabis-products-meet-minimum-quality-standard> Cannasouth products will be added by the Ministry of Health in due course.

-ENDS-

For further information visit www.cannasouth.co.nz or contact:

Mark Lucas

CEO / Executive Director
Email: mark.lucas@cannasouth.co.nz
Mobile: 021 484 649

Colin Foster

CFO / Company Secretary
Email: colin.foster@cannasouth.co.nz
Mobile: 027 577 1498

About Cannasouth Limited

Cannasouth is a vertically integrated biopharmaceutical Group. The Group has been established to focus on the commercial development of the medicinally beneficial attributes of cannabinoid compounds produced by the cannabis plant, and other health products and medicines. Our goal is to support patients' health outcomes and improve their quality of life. Our products are produced under GMP, using environmentally friendly methods, ensuring patients are treated with therapeutic products of the highest quality. Cannasouth Limited is the parent company, listed on the NZX, and is 100% owner of Cannasouth Bioscience Ltd, Cannasouth Cultivation Ltd and Equalis Group New Zealand Ltd.

For video footage, photos and logos please visit: <https://www.cannasouth.co.nz/about/media/>